Wuhan, China -
Mesenchymal stem cells are most likely to be the first clinically approved stem cell type in the United States for non-hematopoietic conditions, with several clinical trials in mid to late Phase III. Mesenchymal stem cells are attractive because they can be used in a "universal donor" fashion, in part due to their immune modulatory...
Santiago, Chile -
A recent paper (Ezquer et al. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant 008 Jun;14(6):631-40) described the therapeutic impact of bone marrow derived mesenchymal stem cells administered to mice with experimental...
In this StemCellPatents.com interview, our special guest interviewer, Thomas Ichim, CEO of Medistem, speaks with Alan Lewis, CEO of Novocell, regarding the company's advances towards curing diabetes. This interview examines many aspects of Novocell...
Gainsville, Florida -
Autologous cord blood has received some recent media for its use in treatment of cerebral palsy. Other groups have reported the use of allogeneic cord blood to have positive effects for conditions other than hematopoietic disorders, even in absence of immune... Brussels, Belgium -
Numerous tissue have been described to have endogenous, tissue resident, stem cells. For example, cardiac tissues express a population of lineage negative, side population cells that can regenerate myocardium. These cells and their uses are claimed in US patent 7,097,833. The side population phenotype has... Taipei, Taiwan -
In addition to their known ability to differentiate into muscle, bone, and neuronal cells, mesenchymal stem cells have been demonstrated to have the ability to differentiate into
CD133 glycosylated epitope of prominin-1 is marker for pancreatic stem cells
Bone Marrow Mesenchymal Stem Cells Made to Produce Insulin